MedTrace Logo

Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients

NCT01382303 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2017-06-16

Study results available
· View outcomes & findings →

Summary

This multi-center, randomized controlled study aims to evaluate the effects of pentoxifylline on proteinuria in Korean type 2 diabetic patients.

Conditions

Interventions

DRUG

Pentoxifylline

Pentoxifylline 400mg three times a day

DRUG

Placebo

placebo tablet three times a day

Sponsors & Collaborators

  • Bundang CHA Hospital

    collaborator OTHER

  • Hallym University Medical Center

    collaborator OTHER

  • Gangnam Severance Hospital

    collaborator OTHER

  • Yonsei University

    collaborator OTHER

  • Myongji Hospital

    collaborator OTHER

  • Ajou University School of Medicine

    lead OTHER

Principal Investigators

  • Kwan-Woo Lee, PhD · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-25
Primary Completion
2013-12-20
Completion
2013-12-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01382303 on ClinicalTrials.gov